New institute to study RNA medicine; Alnylam adds to board of directors;

> The Cancer Center at Beth Israel Deaconess Medical Center in Boston launched a new Institute for RNA Medicine. Story

> Alnylam Pharmaceuticals ($ALNY) added Amy Schulman to its board of directors. Release

> Ophthalmology company Icon Bioscience completed enrollment of its Phase III trial for an injected, sustained-release formulation of the anti-inflammatory agent dexamethasone following cataract surgery. Release

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.